Skip to main content
. 2022 Jan 26;23(3):1391. doi: 10.3390/ijms23031391

Figure 2.

Figure 2

The SCA3 PPs exhibited pathological characteristics after the treatment of QA. The control and SCA3 PPs were treated with 1 μM of QA for 12 h. (A) The representative morphological observation and the quantification of neurite length analysis of control- and SCA3 PPs from three independent images. Scale bar = 100 μm. Data are presented as the means ± standard deviation; t(28) = 6.945, p < 0.01, for Control PPs vs. Control PPs with QA; t(28) = 14.16, p < 0.01, for Control PPs vs. SCA3 PPs with QA; (B) protein analysis of PARP1 in cell lysates of control and SCA3 PPs by immunoblots under the treatment of QA in the presence of variable concentrations of n-BP. Statistics refer to lane 1 to lane 3 of Figure 3D. Data are presented as the means ± standard deviation. t(4) = 5.876, p < 0.01, for SCA3 PPs vs. SCA3 PPs with QA; (C) the representative image of ATXN3 nucleus co-localization assessed by ICC assay. The co-localization is indicated using white arrowheads and the quantification data from three independent images are presented as the means ± standard deviation. t(4) = 13.74, p < 0.01, for SCA3 PPs vs. SCA3 PPs with QA; Scale bar = 100 μm; (D) protein analysis of wild-type, mutant ATXN3 and its proteolytic fragment in cell lysates of control and SCA3 PPs by immunoblots. Sol, soluble protein; Insol, insoluble protein form. **, p < 0.01.